295 related articles for article (PubMed ID: 36685541)
21. First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis.
Zhu Y; Liu K; Yang Q; Zeng M; Peng L
Front Public Health; 2023; 11():1028202. PubMed ID: 37006537
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma.
Zheng Z; Fang L; Cai H; Zhu H
Immunotherapy; 2023 Sep; 15(13):1045-1055. PubMed ID: 37401267
[No Abstract] [Full Text] [Related]
23. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
Du J; Wang X; Fan L; Shan X; Li M; Liu L
Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
[TBL] [Abstract][Full Text] [Related]
24. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
25. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.
Liu G; Kang S
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):85-91. PubMed ID: 33627014
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
Li F; Chen Y; Xiao D; Jiang S; Yang Y
Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
[TBL] [Abstract][Full Text] [Related]
28. Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China.
Long Y; Wang H; Xie X; Li J; Xu Y; Zhou Y
BMJ Open; 2024 Apr; 14(4):e077090. PubMed ID: 38582540
[TBL] [Abstract][Full Text] [Related]
29. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China.
Li LY; Wang H; Chen X; Li WQ; Cui JW
Chin Med J (Engl); 2019 Dec; 132(23):2790-2794. PubMed ID: 31856049
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer.
You M; Chen R; Wu Q; Zhu W; He Y; Huang Y
Front Pharmacol; 2022; 13():1019826. PubMed ID: 36386191
[No Abstract] [Full Text] [Related]
31. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
32. First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis.
Zhu Y; Hu H; Ding D; Li S; Liao M; Shi Y; Huang J
Cost Eff Resour Alloc; 2021 Dec; 19(1):77. PubMed ID: 34863203
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China.
Ma Y; Zhou J; Ye Y; Wang X; Ma A; Li H
Front Oncol; 2023; 13():1113346. PubMed ID: 37182176
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
[TBL] [Abstract][Full Text] [Related]
35. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
[TBL] [Abstract][Full Text] [Related]
36. A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial.
Li J; Xu C; Yuan S
Cost Eff Resour Alloc; 2024 Jan; 22(1):8. PubMed ID: 38281053
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
[TBL] [Abstract][Full Text] [Related]
38. Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2.
Schluckebier L; Garay OU; Zukin M; Ferreira CG
Lung Cancer; 2015 Sep; 89(3):274-9. PubMed ID: 26143106
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
